IONS Ionis Pharmaceuticals Inc.

49.14
-1.66  -3%
Previous Close 50.8
Open 50.83
Price To Book 9.69
Market Cap 6745639790
Shares 137,273,907
Volume 1,728,030
Short Ratio 9.91
Av. Daily Volume 1,107,326

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181049044
  2. CT ORDER - Confidential treatment order 181036292
  3. 8-K - Current report 181039596
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999149
  5. 8-K - Current report 18996915

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2b initiated.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 1/2 data presented April 24, 2018 at AAN.
IONIS-HTT Rx
Huntington's Disease
Phase 2b completion of enrollment announced February 7, 2018. Data due 2H 2018.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review extended to October 6, 2018.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 1/2 data possibly due 2H 2018.
IONIS-SOD1Rx
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. What Sarepta Therapeutics’ Valuation Trend Indicates
  2. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  3. A Look at Spectrum’s Financial Position in September
  4. Why Arrowhead Pharmaceuticals Stock Is Skyrocketing Today
  5. Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?
  6. 3 Big Stock Charts for Wednesday: PG&E, PepsiCo and Hewlett Packard Enterprise
  7. Ionis stock drops 13% as FDA fails to approve key drug
  8. Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
  9. Why Canopy Growth, Mitek Systems, and Ionis Pharmaceuticals Slumped Today
  10. A Look at Portola Pharmaceuticals’ Financial Position
  11. Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today
  12. Why Analysts Are Positive on Portola Pharmaceuticals in August
  13. Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback
  14. Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session
  15. The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic
  16. Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
  17. After-hours buzz: AMD, AKCA, IONS & more
  18. FDA rejects rare disease drug developed by Cambridge's Akcea
  19. Akcea, Ionis shares drop after disappointing FDA decision